Celltex Therapeutics has secured approval from the U.S. Food and Drug Administration to move forward with their treatment for COVID-19, which involves autologous adipose tissue-derived mesenchymal stem cells (AdMSCs). These AdMSCs will be evaluated for efficacy in a multi-center, randomized, double-blind, placebo-controlled phase II trial. In order to ease the burden on patients, Yourway offers direct-to-patient (DTP) clinical trials, which do not require travel. This direct and efficient way of conducting trials has also been available throughout the pandemic.